CLAIMS

What is claimed is:

1. A composition comprising an oligonucleotide that inhibits the expression of Macrophage stimulating protein 1 (MST1) for use in therapy, wherein the subject has a lung disorder and, wherein the oligonucleotide comprises an siRNA comprising an antisense strand 12-30 nucleosides in length, comprising SEQ ID NO:6023.
2. The composition according to claim 1, wherein the lung disorder comprises COPD, acute exacerbation of COPD, emphysema, chronic bronchitis, asthma, status asthmaticus, asthma-COPD overlap syndrome (ACOS), cough, dyspnea, lung cancer, interstitial lung disease, or pulmonary fibrosis.
3. The composition according to any one of claims 1 or 2, wherein any one of the following is true with regard to the sense strand:

   all purines comprise 2'-fluoro modified purines, and all pyrimidines comprise a mixture of 2'-fluoro and 2'-O-methyl modified pyrimidines;

   all purines comprise 2'-O-methyl modified purines, and all pyrimidines comprise a mixture of 2'-fluoro and 2'-O-methyl modified pyrimidines;

   all purines comprise 2'-fluoro modified purines, and all pyrimidines comprise 2'-O-methyl modified pyrimidines;

   all pyrimidines comprise 2'-fluoro modified pyrimidines, and all purines comprise a mixture of 2'-fluoro and 2'-O-methyl modified purines;

   all pyrimidines comprise 2'-O-methyl modified pyrimidines, and all purines comprise a mixture of 2'-fluoro and 2'-O-methyl modified purines; or

   all pyrimidines comprise 2'-fluoro modified pyrimidines, and all purines comprise 2'-O-methyl modified purines.
4. The composition of claim 14, wherein any one of the following is true with regard to the antisense strand:

   all purines comprise 2'-fluoro modified purines, and all pyrimidines comprise a mixture of 2'-fluoro and 2'-O-methyl modified pyrimidines;

   all purines comprise 2'-O-methyl modified purines, and all pyrimidines comprise a mixture of 2'-fluoro and 2'-O-methyl modified pyrimidines;

   all purines comprise 2'-O-methyl modified purines, and all pyrimidines comprise 2'-fluoro modified pyrimidines;

   all pyrimidines comprise 2'-fluoro modified pyrimidines, and all purines comprise a mixture of 2'-fluoro and 2'-O-methyl modified purines;

   all pyrimidines comprise 2'-O-methyl modified pyrimidines, and all purines comprise a mixture of 2'-fluoro and 2'-O-methyl modified purines; or

all pyrimidines comprise 2’-O-methyl modified pyrimidines, and all purines comprise 2’-fluoro modified purines.

5. The composition according to any one of claims 1 to 4, wherein


(a) the sense strand comprises modification pattern 5'-snnnnnnNfnNfNfnnnnnnnnnsnsn-3';

(b) the antisense strand comprises modification pattern 5'nsNfsnnnnNfnnNfnNfnNfnNfnNfnsnsn-3'; or

both (a) and (b),


wherein n is 2'-O-methyl (2'-OMe) A, G, C, and U, respectively; Nf is 2'-fluoro (2'-F) A, G, C, and U, respectively; and s is a phosphorothioate linkage; and the appropriate number of additional nucleotides added 5’ or 3’ to match the number of nucleotides in the modification pattern.

6. The composition according to any one of claims 1 to 5**,** wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 2999.
7. The composition according to any one of claims 1 to 6, wherein the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 6385.
8. The composition according to any one of claims 1 to 7, wherein the antisense strand comprises an oligonucleotide sequence of SEQ ID NO: 6415.
9. The composition according to any one of claims 1-8, wherein the modified oligonucleotide is conjugated to a sugar moiety attached at a 5' or 3' terminus of the sense strand or antisense strand.
10. The composition of claim 9, wherein the sugar moiety comprises N-acetylgalactosamine (GalNAc), N-acetylglucosamine (GlcNAc), or mannose.
11. The composition of claim 10, wherein the sugar moiety is conjugated to the 5' terminus of the sense strand.
12. The composition of any one of claims 9-11, wherein the sugar moiety comprises the structure:



wherein J is the attachment point to the 5' phosphorothioate linkage of the sense strand.

13. The composition according to claim 12, wherein the sugar moiety comprises



14. The composition of any one of claims 1-13, wherein

(i) the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 6229 and the antisense strand comprises an oligonucleotide sequence of SEQ ID NO: 6288; or

(ii) the sense strand comprises an oligonucleotide sequence of SEQ ID NO: 6234 and the antisense strand comprises an oligonucleotide sequence of SEQ ID NO: 6294.

15. The composition according to any one of claims 1 to 14, further comprising a pharmaceutically acceptable carrier.
16. Use of a composition according to any one of claims 1 to 15 in the manufacture of a medicament for treating a subject having a lung disorder.
17. The use of claim 16, wherein the lung disorder comprises COPD, acute exacerbation of COPD, emphysema, chronic bronchitis, asthma, status asthmaticus, asthma-COPD overlap syndrome (ACOS), cough, dyspnea, lung cancer, interstitial lung disease, or pulmonary fibrosis.